^
Association details:
Biomarker:NRAS G13D + BRAF V600E
Cancer:Thyroid Gland Carcinoma
Drug Class:BRAF inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Published date:
09/08/2020
Excerpt:
Patients 1 and 3 acquired a KRASG12V mutation in the progressive tumor, patient 2 acquired a NRASQ61K mutation in a progressive lymph node, and patient 4 acquired NRASG13D mutation on liquid biopsy performed at the time of radiographic disease progression....the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.
DOI:
10.1089/thy.2019.0514